Clinicopathological analysis of small-sized thymoma with podoplanin and Ki 67 expression analysis

Yokota,Keisuke; Tateyama,Hisashi; Yano,Motoki; Moriyama,Satoru; Hikosaka,Yu; Okuda,Katsuhiro; Shitara,Masayuki; Okumura,Meinoshin; Yokoi,Kohei; Fujii,Yoshitaka

doi:10.3892/mco.2012.2

Clinicopathological analysis of small-sized thymoma with podoplanin and Ki 67 expression analysis

Authors:
- Keisuke Yokota
- Hisashi Tateyama
- Motoki Yano
- Satoru Moriyama
- Yu Hikosaka
- Katsuhiro Okuda
- Masayuki Shitara
- Meinoshin Okumura
- Kohei Yokoi
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, Department of Pathology, Kasugai Municipal Hospital, Kasugai, Japan, Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, Division of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Published online on: June 8, 2012 https://doi.org/10.3892/mco.2012.2
Pages: 88-92

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymoma is the most common tumor of the anterior mediastinum for which surgical resection is currently the primary form of treatment. An increase in the incidence of a small-sized (≤3 cm) thymoma (SST) has recently been noted. Clinicopathological factors and prognosis of SST have not been reported previously. In this study, the clinicopathological data of 21 SST patients were reviewed and podoplanin and Ki67 immunohistochemistry were assessed to determine the biological behavior of SSTs. Pathological diagnosis of SSTs revealed the following types: A (n=1), AB (n=8), B1 (n=5), B2 (n=6) and B3 (n=1). The Masaoka-Koga stages of 21 thymoma patients were I (n=16), II (n=3), III (n=1) and IVb (n=1). In the case of the stage IVb thymoma, phrenic nerve, mediastinal pleura invasion and anterior mediastinal lymph node metastasis were observed. The Ki67 labeling index of this stage IVb was found to be 3.2. This case was also positive for podoplanin and was one of the only 2 cases that were positive for podoplanin. This patient succumbed to thymoma. Advanced stage thymomas are possibly included in SSTs although the majority of SSTs are classified into early stages of disease. Findings of this study suggest that podoplanin analyzed by immunohistochemistry may be useful to determine the malignant behavior of SSTs.

View Figures

View References

1.	Masaoka A, Monden Y, Nakahara K and Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer. 48:2485–2492. 1981.
2.	Blumberg D, Port JL, Weksler B, et al: Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg. 60:908–913. 1995.
3.	Kondo K and Monden Y: Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 76:878–884. 2003.
4.	Tateyama H, Mizuno T, Tada T, Eimoto T, Hashimoto T and Masaoka A: Thymic epithelial tumours: evaluation of malignant grade by quantification of proliferating cell nuclear antigen and nucleolar organizer regions. Virchows Arch A Pathol Anat Histopathol. 422:265–269. 1993.
5.	Tateyama H, Eimoto T, Tada T, Mizuno T, Inagaki H, Hata A, Sasaki M and Masaoka A: p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study. Am J Clin Pathol. 104:375–381. 1995.
6.	Pich A, Chiarle R, Chiusa L, Ponti R, Geuna M, Casadio C, Maggi G and Palestro G: Long-term survival of thymoma patients by histologic pattern and proliferative activity. Am J Surg Pathol. 19:918–926. 1995.
7.	Yang WI, Efird JT, Quintanilla-Martinez L, Choi N and Harris NL: Cell kinetic study of thymic epithelial tumors using PCNA (PC10) and Ki-67 (MIB-1) antibodies. Hum Pathol. 27:70–76. 1996.
8.	Chen FF, Yan JJ, Jin YT and Su IJ: Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol. 27:1089–1092. 1996.
9.	Tateyama H, Eimoto T, Tada T, Inagaki H, Hattori H and Takino H: Apoptosis, bcl-2 protein, and Fas antigen in thymic epithelial tumors. Mod Pathol. 10:983–991. 1997.
10.	Takahashi E, Tateyama H, Akatsu H, Fukai I, Yamakawa Y, Fujii Y and Eimoto T: Expression of matrix metalloproteinases 2 and 7 in tumor cells correlates with the World Health Organization classification subtype and clinical stage of thymic epithelial tumors. Hum Pathol. 34:1253–1258. 2003.
11.	Tateyama H, Sugiura H, Yamatani C and Yano M: Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome. Hum Pathol. 42:533–540. 2011.
12.	Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T and Shimosato Y: A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 44:359–367. 1994.
13.	Huang J, Detterbeck FC, Wang Z and Loehrer PJ Sr: Standard outcome measures for thymic malignancies. J Thorac Oncol. 5:2017–2023. 2010.
14.	Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: World Health Organization classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: pp. 146–151. 2004
15.	Onuki T, Ishikawa S, Iguchi K, et al: Limited thymectomy for stage I or II thymomas. Lung Cancer. 68:460–465. 2010.
16.	Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H and Masaoka A: The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer. 94:624–632. 2002.
17.	Pollack A, DeSilvio M, Khor LY, et al: Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol. 22:2133–2140. 2004.
18.	Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010.
19.	Ghazi AA, Dezfooli AA, Mohamadi F, Yousefi SV, Amirbaigloo A, Ghazi S, Pourafkari M, Berney D, Ellard S and Grossman AB: Cushing syndrome secondary to a thymic carcinoid tumor due to multiple endocrine neoplasia type 1. Endocr Pract. 17:e92–e96. 2011.